Palbociclib
Ibrance · CDK4/6 inhibitor
Generally renally well tolerated.
Kisqali · Ribo
CDK4/6 inhibitor · approved 2017 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
CDK4/6 inhibitor whose creatinine bump is mostly transporter inhibition, with QT prolongation to watch.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Like other CDK4/6 inhibitors, ribociclib produces a frequent, reversible creatinine rise via inhibition of tubular creatinine secretion (pseudo-AKI ~14% in a class-effect analysis); clinically meaningful structural AKI is uncommon. A retrospective cohort of palbociclib/ribociclib patients found a >=20% creatinine-clearance decline in about 23%.Source: Ly et al., J Oncol Pharm Pract 2026 (PMID 39648753 — source of the 14% headline: pseudo-creatinine elevation in 6/43 ribociclib patients, all grade 1-2); Avci et al., Ther Adv Med Oncol 2026 (PMID 41523909 — a different endpoint: ≥20% CrCl decline in 28/120 (23%) of a mixed palbociclib/ribociclib cohort). Most ribociclib creatinine rise is transporter-mediated pseudo-AKI, not structural injury.
The creatinine signal appears in the first cycles (median onset roughly 6 weeks) and reverses on hold or discontinuation, with QTc effects seen early.
Distilled from: “First cycles (median onset roughly 6 weeks for the creatinine signal); reversible on hold or discontinuation. QTc effects are dose- and concentration-dependent and seen early.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Class effect: predominant renal signal is pseudo-AKI (creatinine rise from OCT2/MATE inhibition without a real GFR decline); true AKI (acute tubular injury, interstitial nephritis) is rare PMID 41385991 (opens PubMed in a new tab)
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Hypokalemia/hyponatremia reported but uncommon relative to the near-universal creatinine change PMID 41385991 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
Representative incidence
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Selective CDK4/6 inhibitor that halts the cell cycle at the G1/S checkpoint by preventing Rb phosphorylation; combined with endocrine therapy in HR-positive, HER2-negative advanced/metastatic breast cancer, with a demonstrated overall-survival benefit (e.g. MONALEESA-7: median OS 58.7 vs 48.0 months).
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Jul 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dose adjustment is necessary in patients with breast cancer who have mild to moderate (30 mL/min to 89 mL/min/1.73 m 2 ≤ estimated glomerular filtration rate (eGFR)) renal impairment. A reduced starting dose of 200 mg is recommended in patients with breast cancer who have severe renal impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)] .
Kidney rows of the label's dosage tables
From the KISQALI label (Jul 2026) · DailyMed
No row of this label's 9 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 32,716 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
4,684 of 32,716 reports
Reported with hospitalization
7,508 of 32,716 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 3 of the 32,716 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ribociclib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Ibrance · CDK4/6 inhibitor
Generally renally well tolerated.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Koselugo · MEK inhibitor
Creatinine rise in neurofibromatosis.
Verzenio · CDK4/6 inhibitor
Benign creatinine rise via tubular secretion block.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Ribociclib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Ribociclib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 14 clinical records among all 19 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.